Predictive potential of *IL-28B* genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective

Muhammad Sohail Afzal

Muhammad Sohail Afzal, Department of Chemistry, School of Science, University of Management and Technology, Lahore 54000, Pakistan

**Author contributions:** Afzal MS designed the research, analyzed the data, wrote the letter, and revised the letter.

**Conflict-of-interest statement:** Afzal MS declares that there is no conflict of interest in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Muhammad Sohail Afzal, PhD, Department of Chemistry, School of Science, University of Management and Technology, C-11 Johar Town, Lahore 54000, Pakistan. sohail.ncvi@gmail.com

**Telephone:** +92-321-5244808

Received: April 5, 2016
Peer-review started: April 5, 2016
First decision: May 17, 2016
Revised: June 29, 2016
Accepted: July 20, 2016
Article in press: July 22, 2016
Published online: September 18, 2016

**Abstract**

In Pakistan which ranked second in terms of hepatitis C virus (HCV) infection, it is highly needed to have an established diagnostic test for antiviral therapy response prediction. Interleukin 28B (*IL-28B*) genetic testing is widely used throughout the world for interferon based therapy prediction for HCV patients and is quite helpful not only for health care workers but also for the patients. There is a strong relationship between single nucleotide polymorphisms at or near the *IL-28B* gene and the sustained virological response with pegylated interferon plus ribavirin treatment for chronic hepatitis C. Pakistan is a resource limited country, with very low per capita income and there is no proper social security (health insurance) system. The allocated health budget by the government is very low and is used on other health emergencies like polio virus and dengue virus infection. Therefore it is proposed that there should be a well established diagnostic test on the basis of *IL-28B* which can predict the antiviral therapy response to strengthen health care set-up of Pakistan. This test once established will help in better management of HCV infected patients.

**Key words:** Diagnostics; Hepatitis C virus; Interferon therapy; Polymorphisms; *IL-28B*; Genetic testing; Pakistan

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Pakistan has a very heavy burden of hepatitis C virus (HCV) infection with around 11 million positive cases; however, in spite of well established prognostic value, the data regarding the role of interleukin 28B (*IL-28B*) single nucleotide polymorphisms (SNPs) in HCV antiviral therapy response are very limited. There are only six reports on the topic and it can be concluded from this limited information that *IL-28B* could be a good prognosis marker for HCV patient management in Pakistan. The major prevalent HCV genotype in Pakistan is 3a and *IL-28B* SNP rs12979860 showed a good prediction for interferon based antiviral therapy response against this viral genotype. It can be predicted that inclusion of *IL-28B* genetic testing in...
routine diagnostic set-up of Pakistan will help in better management of the disease. A well directed antiviral therapy based on personalized IL-28B genotyping along with virus genotyping will help in lessening of therapy cost and better management of the disease.

Afzal MS. Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective. World J Hepatol 2016; 8(26): 1116-1118 Available from: URL: http://www.wjgnet.com/1948-5182/full/v8/i26/1116.htm DOI: http://dx.doi.org/10.4254/wjh.v8.i26.1116

TO THE EDITOR

Recent advancements in molecular biology techniques help in identification of various host and pathogenic factors influencing the disease prognosis and therapeutic outcomes. One example is identification of various genetic factors through genome wide analysis studies (GWAS). In the field of gastroenterology and hepatology, an example is the discovery of an association between single nucleotide polymorphisms (SNPs) at or near the interleukin 28B (IL-28B) gene and the sustained virological response (SVR) rate with pegylated interferon (IFN) plus ribavirin treatment for chronic hepatitis C (CH-C)[1-3]. IL-28B (IFN-λ) is produced by many immune cells like neuronal cells, alveolar epithelial cells, and hepatocytes in response to viral infection. IFN-λ showed antiviral activity against many viruses. It not only inhibits viral replication but also has immune-modulatory functions[4]. It has been shown by four autonomous GWAS that SNPs of the IL-28B gene, which is located on chromosome 19q13, are strongly associated with treatment response to interferon based therapy and spontaneous viral clearance in chronic hepatitis C virus (HCV)-infected patients[4]. After these studies, the predictive potential of IL-28B genetic variations has been investigated and verified throughout the world in patients infected with HCV of all viral genotypes and currently IL-28B SNPs are in commercial use for antiviral therapy response prediction around the world.

In Pakistan, data regarding the role of IL-28B SNPs in HCV antiviral therapy response are very limited. To our knowledge, there are only six studies that investigated the role of IL-28B in HCV patients regarding interferon therapy response and disease prognosis (Table 1)[5-10]. These studies investigated the predictive potential of either IL-28B protein level or IL-28B SNPs (rs12979860, rs8099917, rs12980275). It can be concluded from existing limited data that IL-28B could be a good prognosis marker for HCV patient management. Recent studies by Shaikh et al[6] (2014) and Imran et al[8] (2015) reported significant existence (47.5% and 6.4%, respectively) of circulation of diagnostically untypable HCV variants in local populations of Sindh Province of Pakistan. We have lately highlighted the issue of diagnostically untypable HCV circulation in Pakistan and recommended immediate need to resolve this problem for the better management of HCV patients as course and fate of antiviral therapy are viral genotype dependent[11]. The resolution of this problem will also help in understanding the potential role of IL-28B SNPs in antiviral therapy response prediction against each viral genotype.

HCV is highly endemic in Pakistan with around 11 million infections[12-14]. The major prevalent viral genotype is 3a along with 2a, 3b, 1b, 2b, 2a and a large number of untypable ones[11,15,16]. It is observed that irrespective of the HCV genotype, SVR rate of interferon plus ribavirin is quite good (80%-97%) in Pakistan[7,12,17,18]. Pakistan is a resource limited country with much low per capita income in the general population. According to the World Health Organization, the total expenditure on health is only 2.8% of GDP, which means total expenditure on health per capita is only 126 $[19]. Other medical emergencies like polio virus and dengue virus endemics shift the government priorities and funds are becoming less available for HCV management. There is no health insurance for the general population in Pakistan, which also affect the patient’s ability to bear therapy cost. IL-28B genetic test is an established diagnostic test for interferon based antiviral therapy response prediction across the world. In the current scenario of Pakistan, it is highly needed to have an established diagnostic test on the basis of IL-28B which can predict the antiviral therapy response.

The currently available literature on the role of IL-28B in HCV interferon therapy response in Pakistan shows that rs12979860 is a good predictor of therapy response against HCV 3a genotype. In the era of direct acting antivirals (DAAs), interferon based therapy against HCV will remain the major choice in Pakistan due to higher SVR and low cost compared with DAAs[20]. On the basis of the above discussion, we propose future studies across the country on different ethnic groups infected with all viral genotypes so that the results could be generalized for diagnostic purpose. It is also suggested that the forthcoming studies should include a comparatively larger number of patients so that the results could be applicable for commercial purpose. It is highly anticipated that inclusion of IL-28B genetic testing in routine diagnostic tests will help health care professionals in better management of the patients. Well directed antiviral therapy on the basis of personalized IL-28B genotyping along with viral genotyping will help in reduction of therapy cost and better management of the disease.
Table 1 Summary of interleukin 28B and interferon based therapy response in hepatitis C virus patients in Pakistan

| Year | Viral genotype | Patients (n) | Objective/SNP investigated | Findings/conclusion | Ref. |
|------|----------------|-------------|----------------------------|---------------------|-----|
| 2015 | 3a             | 66          | IL-28B protein levels      | IL-28B protein levels were significantly associated with therapy response | [5] |
| 2015 | 3              | 105         | rs8099917, rs12979860      | TT genotype favors RVR | [6] |
| 2015 | 1a,1b, 3a      | 111         | rs12979860                 | CC genotype favors SVR | [7] |
| 2015 | 1a, 1b, 3a, 3b, 4, UT | 140 | rs8099917, rs12979860 | No association was observed with therapy response | [8] |
| 2014 | (2a, 3a, UT)   | 220         | rs12980275                 | No association was observed with therapy response | [9] |
| 2014 | 3a             | 200         | rs12979860                 | AA genotype favors SVR | [10] |

Genotyping performed only for non-responders patients. SVR: Sustained virological response; RVR: Rapid virological response; UT: Un_typable; IL-28B: Interleukin 28B; HCV: Hepatitis C Virus; SNP: Single nucleotide polymorphism.

REFERENCES

1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urbanek S, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]

2. Suppiah V, Moldovan M, Ahlenstiel G, Berthold FR, Gahl WA, Strotmann R, et al. Genotype-specific IL-28B protein levels in chronic hepatitis C virus patients. J Hepatol 2015; 62: 558-565 [PMID: 25353277 DOI: 10.1016/j.jhep.2014.10.002]

3. Tanaka Y, Nishida N, Sugiyama M, Kurokaki M, Matsuura K, Sakamoto T, et al. Genotypes of the IL-28B gene in patients with chronic hepatitis C virus infection. J Viral Hepat 2015; 22: 29-36 [PMID: 25516688 DOI: 10.1111/jmv.12555]

4. Imran M, Manzoor S, Aslam B, Waheed Y, Shafi T, Qadri MH, et al. Distribution of Interleukin-28B polymorphisms in chronic hepatitis C patients in Pakistan. Genet Med 2016; 18: 188-194 [PMID: 25563877 DOI: 10.1038/gim.2015.142]

5. Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL-28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon-α therapy. J Med Virol 2017; 89: 945-950 [PMID: 27589275 DOI: 10.1002/jmv.24987]

6. Akhtar N, Bilal M, Rizwan M, Khan MA, Khan A. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhwa, Pakistan. Pak J Med Sci 2016; 32: 900-903 [PMID: 26708904 DOI: 10.10111/jmv.2015.12.021]

7. Ahmad B, Ali S, Ali I, Azam S, Bashir S. Response rates of standard interferon therapy in chronic hepatitis C patients of Khyber Pakhtunkhwa. J Med Virol 2016; 88: 1037-1040 [PMID: 25735237 DOI: 10.1002/jmv.24987]

8. Hashmi AH, Ahmad N, Riaz S, Ali I, Siddiqui S, Khan KM, Shakeri AR, Manzoor A. Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection. Genes Immun 2015; 16: 430-432 [PMID: 24898388 DOI: 10.1038/gene.2014.31]

9. Afzal MS, Khan MY, Ammar M, Anjum S, Zaidi NU. Diagnostically untypable hepatitis C virus variants: it is time to resolve the problem. J World Gastroenterol 2016; 20: 17690-17692 [PMID: 25516688 DOI: 10.3748/wjg.v20.i46.17690]

10. Afzal MS, Anjum S, Zaidi NU. Changing of HCV clade pattern in Iran; the possible means for something good. Hepat Mon 2014; 14: 11879 [PMID: 24497875 DOI: 10.5812/hepatmon.11879]

11. Afzal MS, Ahmed T, Zaidi NU. Comparison of HCV prevalence in Pakistan and Iran; an insight into future. Hepat Mon 2014; 14: 11466 [PMID: 24947874 DOI: 10.5812/hepatmon.11466]

12. Afzal MS, Zaidi NU, Alkahlal RM, Afzal MS, Khaliq HM, Azam S. Role of viral and host factors in interferon based therapy of chronic hepatitis C. Interleukin-28B: a prognostic marker in chronic hepatitis C patients with variable treatment response. J Med Virol 2016; 88: 857-862 [PMID: 25793946 DOI: 10.1002/jmv.24988]

13. Afzal MS, Azam S, Manzoor S, Khan MA, Khan M, Ali L, Siddiqui S, Khan KM, Riaz S, Ahmad N, et al. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhwa, Pakistan. Asian Pac J Cancer Prev 2016; 17: 509-512 [PMID: 25793945 DOI: 10.19178/ajpcr.2016.17.2.2760]

14. Afzal MS, Akhtar N, Bilal M, Rizwan M, Khan MA, Khan A. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhwa, Pakistan. Asian Pac J Cancer Prev 2016; 17: 1037-1040 [PMID: 25735227 DOI: 10.22034/apjcp.2016.17.3.1037]

15. Afzal MS, Shah BH, Ahmad T, Zaidi NU. Genotype changing pattern in the Khyber Pakhtunkhwa province of Pakistan; is it pointing out a forthcoming problem? Braz J Infect Dis 2016; 20: 312-313 [PMID: 2643150 DOI: 10.1016/j.bjid.2015.12.011]

16. Anjum S, Afzal MS, Ahmad T, Ashlam B, Waheed Y, Shaht T, Qadri MI. Mutations in the STAT1-interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy. Mol Med Rep 2013; 8: 487-492 [PMID: 23799612 DOI: 10.3892/mmr.2013.1541]

17. Akhtar N, Bilal M, Rizwan M, Khan MA, Khan A. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhwa, Pakistan. Asian Pac J Cancer Prev 2015; 16: 1037-1040 [PMID: 25735237 DOI: 10.22034/apjcp.2016.17.3.1037]

18. Ahmad S, Ali S, Ali I, Azam S, Bashir S. Response rates of standard interferon therapy in chronic hepatitis C patients of Khyber Pakhtunkhwa (KPK). J Med Virol 2012; 9: 18 [PMID: 22244529 DOI: 10.1186/1743-422X-9-18]

19. World health Organization. Pakistan. Available from: URL: www.who.int/countries/pak/en/
